Bermuda Hospitals Board appoints Dana-Farber oncologist as clinical advisor for oncology

Shulman to oversee design and implementation of a new cancer care model

The Bermuda Hospitals Board has named Lawrence N. Shulman, MD, as clinical advisor for oncology. Shulman, who is chief medical officer and senior vice president of medical affairs of the Dana-Farber Cancer Institute, will be responsible for guiding the design and implementation of a new, multi-disciplinary model of cancer care in Bermuda.

Shulman's appointment builds on a growing partnership between Partners International, a subsidiary of Partners HealthCare, and the Bermuda Hospitals Board to improve the delivery of local care and to offer Bermudians the most advanced and innovative medical treatment overseas.

Visiting specialists from Dana-Farber, Brigham and Women's Hospital and Massachusetts General Hospital will work collaboratively with their Bermudian hospital colleagues to develop state-of-the-art cancer treatment plans that will streamline and personalize the care provided on the island.

"I am extremely pleased to be working with Dana-Farber to help improve the access to high quality, specialist cancer care for the people of Bermuda," said David Hill, chief executive officer, Bermuda Hospitals Board. "This agreement will vastly improve the experience of our patients with cancer, who will be able to see Dana-Farber specialists on-island and will have seamless access to one of the world's most renowned and highly regarded cancer centers if they need to travel abroad for treatments that we cannot provide in Bermuda."

Shulman, who is an associate professor of medicine at Harvard Medial School, also is the director of Network Development for the Dana-Farber/Brigham and Women's Cancer Center, where he has led the initiative to establish the first satellite oncology centers in the greater Boston area. He also has overseen clinical affiliations between Dana-Farber and health care facilities in six countries.

Bermuda Hospitals Board

The Bermuda Hospitals Board is a quasi autonomous non-governmental organization established under the Bermuda Hospitals Board Act, 1970. It has a Bermuda Government-approved Board and a Chief Executive Officer, responsible for King Edward VII Memorial Hospital and Mid-Atlantic Wellness Institute. At the heart of both organizations is high quality care to all patients.

With approximately 1600 employees, the Bermuda Hospitals Board is Bermuda's second largest employer. King Edward VII Memorial Hospital and Mid-Atlantic Wellness Institute are the only healthcare organizations in Bermuda accredited by the Canadian Council on Health Services Accreditation, an independent organization whose role is to help hospitals examine and improve the quality of care and service they provide to their clients. In addition to providing an extensive list of services for the community, the Bermuda Hospitals Board is part of a referral network that includes some of the world's leading specialist hospitals.

Partners HealthCare

Founded in 1994 by Harvard Medical School's largest affiliated teaching hospitals, the Massachusetts General Hospital and Brigham and Women's Hospital, Partners HealthCare is a global leader in quality patient care, medical education and biomedical research. As an integrated medical system, Partners provides a full continuum of care to over 1.5 million patients each year.

Partners International

Drawing upon the experience and resources of Partners HealthCare, Partners International collaborates with colleagues overseas to improve health care worldwide. Partners International offers clinical development and management services, patient care services, educational exchanges, clinical program affiliations and opportunities for research collaboration, all tailored to meet the needs of its global partners.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.